Today, demand for coronavirus vaccines in the West is down, but that won’t last. Recall campaigns against the Omicron variant should lead to an increase in claims around next fall. It is with this in mind that the German company BioNTech has announced that it plans to begin delivery of its vaccines specifically adapted to the variant as early as October, reports the Reuters news agency.
BioNTech submitted its first vaccine targeting the BA.1 subvariant, to European medicines regulator EMA last month. Delivery depends on his approval. Its second vaccine targeting the BA.4 and BA.5 subvariants will begin clinical trials this month.
The only downside that could shift BioNTech’s provisional schedule is the shortage of natural gas due to the war in Ukraine. The company has acknowledged some uncertainty as it uses some for the commercial production of its COVID-19 vaccine. However, it says it is not currently affected and is putting measures in place to mitigate the risks.